Educational Programs

Mazen Noureddin, MD, MHSc

Marcelo Kugelmas, MD, FAASLD, FACP

Q&A Mazen Noureddin, MD, MHSc
Marcelo Kugelmas, MD, FAASLD, FACP

NASH with Fibrosis: Disease, MAESTRO program and Resmetirom MOA & Phase 2 Data UpdateManal Abdelmalek, MD, MPH

NASH with Fibrosis: AASLD UpdatesMazen Noureddin, MD

Q&A Rebecca Taub, MD
Manal Abdelmalek, MD, MPH
Mazen Noureddin, MD

The contribution of metabolic co-morbidities and hepatic thyroid hormone dysregulation to the pathophysiology of NASHVlad Ratziu, MD, PhD

Madrigal Clinical Trial ProgrammeRebecca Taub, MD

Resmetirom Mechanism of ActionRebecca Taub, MD

The contribution of metabolic co-morbidities and hepatic thyroid hormone dysregulation to the pathophysiology of NASHVlad Ratziu, MD, PhD

The utilization of biomarkers for the identification of NASH patients and as predictors of treatment response in the clinical settingJörn Schattenberg, MD

Resmetirom as a treatment for NASH: Updates from the MAESTRO Phase 3 clinical trialsStephen A. Harrison, MD, FACP, FAASLD

Questions and Answers Stephen A. Harrison, MD, FACP, FAASLD
Vlad Ratziu, MD, PhD
Jörn Schattenberg, MD

Stephen A. Harrison
MD, FACP, FAASLD

Stephen A. Harrison
MD, FACP, FAASLD

Rebecca Taub
MD

Rebecca Taub
MD

Scott L. Friedman
MD

Wayne Eskridge

Stephen A. Harrison
MD, FACP, FAASLD

Vlad Ratziu
MD, PhD

Impacting NASH: Focus on Liver and Cardiovascular BenefitsZobair M. Younossi
MD, MPH, FACP, FACG, AGAF, FAASLD

Impacting NASH: Focus on Liver and Cardiovascular BenefitsStephen A. Harrison
MD, FACP, FAASLD

Impacting NASH: Focus on Liver and Cardiovascular BenefitsRohit Loomba
MD, MHSc

Impacting NASH: Focus on Liver and Cardiovascular BenefitsSeth J. Baum
MD, FACC, FACPM, FAHA, FNLA, FASPC